Monte Rosa Therapeutics (GLUE) announced the company will present preclinical data on the potential of its highly selective cyclin-dependent kinase 2, CDK2,-directed molecular glue degrader to treat HR-positive/HER2-negative breast cancer at the 2024 San Antonio Breast Cancer Symposium, held December 10-13 in San Antonio, Texas. The data demonstrate that the company’s CDK2-directed MGD, MRT-9643, has superior selectivity compared to clinical-stage CDK2 inhibitors and induced robust downstream CDK2 pathway suppression. When combined with current standard of care therapies, MRT-9643 drove deep tumor regression in preclinical models of HR-positive/HER2-negative breast cancer.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GLUE:
- Monte Rosa Highlights Promising Results in Cancer Study
- Monte Rosa Therapeutics provides development progress on ongoing MRT-2359 study
- Monte Rosa Therapeutics Expands Pipeline with Novartis Deal
- Monte Rosa Therapeutics reports Q3 EPS (29c), consensus (49c)
- Boeing to offer 90M common shares, Philips reports mixed Q3: Morning Buzz